SEC Form 4 · accession 0001209191-18-052146
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Isaac E. Ciechanover
Officer — Chief Executive Officer · Director
Period of report
Sep 22, 2018
Accepted (ET)
Sep 25, 2018 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 22, 2018 | F | 79,328 | $39.85 | D | 733,285 | D | |
| Common StockF2 | holding | — | — | — | 58,678 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold to cover tax obligation from settlement of vested restricted stock units.
- F2Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.